Determining if your HUB should be insourced, outsourced, or a hybrid of those two options is a big decision. And finding the right answer c

What pharma and biotech professionals need to know about the Drug Supply Chain Security Act and new track-and-trace regulations. Full articl

Archbow's experience with program migrations has taught us what to anticipate, how to formulate realistic expectations, and where to fin

The entrance of cell and gene therapies into the market is impacting every corner of the industry. Likewise, the demand for high-quality CG

It’s crucial to appreciate the complexities of global pricing and contracting so that you can prepare the smartest approach. Understanding

For cell and gene therapies, there's a marketplace shift happening from "Supply Chain" to "Demand Chain." Keep up wi

With the right approach, a good team, and a realistic timeline, pharma companies can successfully support their patients in new and exciting

Is your pharma company looking for new ways to drive better outcomes? Try building better patients.

While many large pharma companies – based in the U.S. or elsewhere – have teams dedicated to maximizing revenue opportunities worldwide, the

regulanet® is a network of independent regulatory and market access agencies with representation in over 90 countries throughout the world.

A standard GPO FMV assessment that was good enough last year likely won’t cut it in today’s environment. To meet client demand, Archbow Con

Before saying goodbye to 2018, we took a quick look back at how well we, and the industry, anticipated and prepared for the trends that shap

The IPI could entirely reshape the way pharma thinks about their business model in the U.S. Archbow's international pricing expert answe

Archbow Consulting teamed up with Pharmaceutical Executive in their September 2018 issue to explore how to overcome the fundamental complexi

Copay accumulator solutions aren’t something you can buy off a shelf because customized, negotiated, collaborative approaches are the only s

Poor quality within a HUB can lead to delays in patient treatment, loss of prescriber confidence, and users seeking competitive therapeutic

Finding the best pharma consultant can be a challenge. Follow these three steps to select a consulting partner that is the right fit, right

If gene therapies, digitalization, and copay accumulators are top of mind concerns, you're not alone. Read our takeaways on these pressi

In the wake of copay accumulator growth, pharma companies may be forced to shoulder increased spending to help patients stay on therapy. Six

PharmaDCX, or Pharma Digital Customer Experience, is the integration of digital technology into all areas of business, resulting in fundamen